Not Yet RecruitingNot Applicable

CGM in Acute Ischemic Stroke

82 participantsStarted 2026-04

Plain-language summary

The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management. This study is designed as a non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \>10 mmol/L) during the first 72 hours of hospitalization. Researchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients. Participants will: * Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management * Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization * Receive glucose management according to the assigned monitoring strategy, based on the hospital insulin protocol

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Acute ischemic stroke treated with endovascular therapy (EVT) * Type 2 diabetes mellitus, defined as one of the following: * documented diagnosis of type 2 diabetes mellitus * use of glucose-lowering medication * admission plasma glucose ≥11.1 mmol/L * HbA1c ≥48 mmol/mol (≥6.5%) Exclusion Criteria: * Current pregnancy * Extensive skin infections or dermatological conditions at the intended sensor site * Medical situations known to interfere with CGM accuracy, including: * Hypotension defined as a systolic blood pressure \<100 mmHg at 30 and 60 minutes after admission * Dialysis treatment * Estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m² * Use of medications known to interfere with CGM accuracy, including: * Acetaminophen \>4 g/day * Dopamine * High-dose vitamin C (ascorbic acid) * Hydroxyurea / hydroxycarbamide * Clinically relevant pancreatic disease * Systemic glucocorticoid therapy with a prednisone-equivalent dose \>5 mg/day * Expected admission to an intensive care unit (ICU)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Time spent in hyperglycemia (>10 mmol/L)

Timeframe: During the first 72 hours of hospitalization

Trial details

NCT IDNCT07510919

SponsorIsala

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05

Contact for this trial

Peter R van Dijk, MD PhD

+316 88 624 50 00 p.r.van.dijk@isala.nl

View on ClinicalTrials.gov More Acute Ischemic Stroke trials